文献速递肾癌与肾肿瘤

三项前瞻性研究中肥胖与肾细胞癌发病及生存的关系

Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies.
PubMed 文献 · Eur Urol · 2022-06-14

为厘清肾细胞癌的「肥胖悖论」,研究在HPFS和NHS 1、2队列中分析体重指数(BMI)和体重变化与肾细胞癌发病及生存的关系。累计平均BMI与总肾细胞癌(汇总HR 2.16,95%CI 1.77-2.63)和致死性肾细胞癌(HR 2.03,95%CI 1.37-3.01)风险升高相关;诊断前BMI与肾细胞癌死亡无关,但诊断后首次BMI(HR 0.51,95%CI 0.29-0.89)和诊断前后体重变化(HR 0.52,95%CI 0.29-0.91)与肾细胞癌死亡呈显著负相关。

要点

  • 累计平均BMI≥30 vs 18-<25 kg/m2与总肾细胞癌风险升高相关(汇总HR 2.16,95%CI 1.77-2.63)。
  • 累计平均BMI≥30 vs 18-<25 kg/m2与致死性肾细胞癌风险升高相关(HR 2.03,95%CI 1.37-3.01)。
  • 诊断后首次BMI和诊断前后体重变化与肾细胞癌死亡呈显著负相关(HR 0.51和0.52)。

核心结论

  • 结果支持肥胖是总肾细胞癌和致死性肾细胞癌的危险因素,并提示诊断前后体重下降而非低BMI本身与更差预后相关,从而削弱「肥胖悖论」。

研究设计与样本

  • 在健康专业人员随访研究(HPFS)和护士健康研究(NHS)1和2三项前瞻性研究中,分析BMI和体重变化与肾细胞癌发病及生存的关系。

主要发现

  • 累计平均BMI≥30 vs 18-<25 kg/m2与总肾细胞癌风险升高相关(汇总HR 2.16,95%CI 1.77-2.63;趋势p<0.001)。
  • 累计平均BMI≥30 vs 18-<25 kg/m2与致死性肾细胞癌风险升高相关(HR 2.03,95%CI 1.37-3.01;趋势p<0.001)。
  • 诊断前BMI与肾细胞癌死亡无关。
  • 诊断后首次BMI与肾细胞癌死亡呈显著负相关(HR 0.51,95%CI 0.29-0.89;趋势p=0.006)。
  • 诊断前至诊断后体重变化与肾细胞癌死亡呈显著负相关(HR 0.52,95%CI 0.29-0.91;趋势p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To disentangle the "obesity paradox" in renal cell carcinoma (RCC), we examined associations of body mass index (BMI) and weight change with RCC risk and survival in the Health Professionals Follow-up Study (HPFS) and Nurses' Health Study (NHS) 1 and 2. We estimated cohort-specific and summary covariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for RCC incidence, as well as RCC-specific survival among cases in the pooled HPFS and NHS data. Cumulative average BMI was associated with a higher risk of total RCC (summary HR 2.16, 95% CI 1.77-2.63 for BMI ≥30 vs 18-<25 kg/m2; p trend <0.001) and fatal RCC (HR 2.03, 95% CI 1.37-3.01; p trend <0.001). Prediagnosis BMI was not associated with RCC death. However, first postdiagnosis BMI (HR 0.51, 95% CI 0.29-0.89; p trend 0.006) and prediagnosis to postdiagnosis weight change (HR 0.52, 95% CI 0.29-0.91; p trend 0.001) were significantly inversely associated with RCC death. These results support obesity as a risk factor for total and fatal RCC. They undermine the obesity paradox by suggesting that weight loss around diagnosis, and not low BMI itself, is associated with worse prognosis. PATIENT SUMMARY: We studied obesity in kidney cancer and found that obesity is associated with getting and dying from the disease. Body mass index at diagnosis is not an ideal factor for predicting prognosis, as patients who have lost weight are likely to have more aggressive cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Graff RE, Wilson KM, Sanchez A, et al. Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. Eur Urol. 2022. PMID: 35715363. doi:10.1016/j.eururo.2022.04.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。